Therapy Detail

Therapy Name Ibrutinib + Ublituximab + Umbralisib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ibrutinib Imbruvica PCI-32765 BTK inhibitor 20 EGFR Inhibitor (Pan) 42 HER2 Inhibitor 21 Imbruvica (ibrutinib) is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), which promotes apoptosis and inhibits B-cell mediated signaling pathways, and has additional activity against ERBB2 (HER2) and EGFR (PMID: 20615965, PMID: 21422473, PMID: 27678331). Imbruvica (Ibrutinib) is approved for mantle cell lymphoma and first line treatment of chronic lymphocytic leukemia (
Ublituximab LFB-R603|TG-1101 Ublituximab is a monoclonal antibody that targets CD20 that may induce complement-dependent and antibody-dependent cell-mediated cytotoxicity against B-cells expressing CD20, potentially resulting in increased B-cell death (PMID: 23611989).
Umbralisib RP5264|TGR-1202 PIK3CD inhibitor 24 Umbralisib (TGR-1202) is a selective inhibitor of PIK3CD, which prevents Akt phosphorylation and induces cytotoxicity (J Clin Oncol 32:5s, 2014 (suppl; abstr 2513)).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown B-cell lymphoma not applicable Ibrutinib + Ublituximab + Umbralisib Phase I Actionable In a Phase I trial, Imbruvica (Ibrutinib), TGR01201, and Ublituximab combination treatment resulted in complete response in 14% (1/7) and partial response in 71% of patients with relapsed B-cell lymphoas within 8 weeks of treatment (J Clin Oncol 33, 2015 (suppl; abstr 8501)). detail...
Clinical Trial Phase Therapies Title Recruitment Status